Buoyed by a $50m milestone payment for a MEK inhibitor licensed to Boehringer Ingelheim and in a bid to mitigate the burn on profits, Lupin is considering partnerships for biosimilars, specialty products and other NCEs with recently spun-off oncology assets being first in line for a deal. But FY22 earnings guidance has been lowered.
Lupin Limited is considering partnerships for its research on biosimilars, specialty generics and new chemical entities (NCEs), with several oncology assets recently spun off under wholly owned US subsidiary Lupin Oncology Inc. being first in line for a tie-up.
The strategy seems aimed at speeding up the pace of commercialization while reducing the burn on profits, at a time when the company is witnessing intense generics competition and unanticipated hurdles in scaling up new
Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.
Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.
Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.
